Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,719 JPY | -0.51% | -4.86% | -13.73% |
Apr. 11 | Hisamitsu Pharmaceutical Attributable Profit Up 19% in Fiscal 2024 | MT |
Jan. 12 | Hisamitsu Pharmaceutical Lifts Fiscal-Year Targets as Nine-Month Profit, Net Sales Rise | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company appears to be poorly valued given its net asset value.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Weaknesses
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-13.73% | 1.83B | C | ||
+25.66% | 672B | C+ | ||
+23.97% | 550B | B | ||
-6.51% | 351B | C+ | ||
+14.66% | 317B | B- | ||
+6.63% | 292B | C+ | ||
+3.02% | 211B | B+ | ||
+0.26% | 203B | B- | ||
-11.12% | 144B | C+ | ||
-7.94% | 141B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4530 Stock
- Ratings Hisamitsu Pharmaceutical Co., Inc.